E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation |
|
E.1.1.1 | Medical condition in easily understood language |
Residual or Recurrent Grade 2 Glioma (a type of brain cancer) With an IDH1 or IDH2 Mutation |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018338 |
E.1.2 | Term | Glioma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy of vorasidenib based on radiographic progression-free survival (PFS) per blinded independent review committee (BIRC) compared with placebo in subjects with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation. |
|
E.2.2 | Secondary objectives of the trial |
Key Secondary: • To demonstrate the efficacy of vorasidenib based on time to next intervention (TTNI) compared with placebo.
Other Secondary. To evaluate: • the safety and tolerability of vorasidenib. • vorasidenib and placebo with respect to tumor growth rate (TGR) as assessed by volume per the BIRC. • the efficacy of vorasidenib and placebo based on objective response, complete response (CR) + partial response (PR), time to response, time to CR+PR, duration of response, and duration of CR+PR, with response assessed per the BIRC and the Investigator. • vorasidenib and placebo with respect to overall survival (OS). • vorasidenib and placebo with respect to health-related quality of life (HRQoL) as assessed by the Functional Assessment of Cancer Therapy – Brain (FACT-Br) questionnaire. • vorasidenib and placebo with respect to PFS per the Investigator assessment. • the pharmacokinetics (PK) of vorasidenib and its circulating metabolite AGI 69460 in plasma. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Be at least 12 years of age and weigh at least 40 kg. • Have Grade 2 oligodendroglioma or astrocytoma per WHO 2016 criteria. • Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, gross-total resection), with the most recent surgery having occurred at least 1 year (-1 month) and not more than 5 years (+3 months) before the date of randomization, and no other prior anticancer therapy, including chemotherapy and radiotherapy, and not be in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. • Have confirmed IDH1 (IDH1 R132H/C/G/S/L mutation variants tested) or IDH2 (IDH2 R172K/M/W/S/G mutation variants tested) gene mutation status disease by central laboratory testing during the Prescreening period and available 1p19q status by local testing (eg, fluorescence in situ hybridization [FISH], comparative genomic hybridization [CGH] array, sequencing) using an accredited laboratory. • Have MRI-evaluable, measurable, non-enhancing disease, as confirmed by the blinded independent review committee (BIRC) • Have a Karnofsky Performance Scale (KPS) score (for subjects ≥16 years of age) or Lansky Play Performance Scale (LPPS) score (for subjects >16 years of age) of ≥80%. |
|
E.4 | Principal exclusion criteria |
• Have had any prior anticancer therapy other than surgery (biopsy, sub-total resection, gross-total resection) for treatment of glioma including systemic chemotherapy, radiotherapy, vaccines, small-molecules, IDH inhibitors, investigational agents, laser ablation, etc. • Have features assessed as high-risk by the Investigator, including brainstem involvement either as primary location or by tumor extension, clinically relevant functional or neurocognitive deficits due to the tumor in the opinion of the Investigator (deficits resulting from surgery are allowed), or uncontrolled seizures (defined as persistent seizures interfering with activities of daily life AND failed 3 lines of antiepileptic drug regimens including at least 1 combination regimen). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Radiographic PFS as assessed by the BIRC per modified Response Assessment for Neuro-oncology for Low-Grade Gliomas [RANO-LGG] |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint is PFS, defined as the time from randomization to the first occurrence of radiographic PD by modified RANO-LGG assessed by the BIRC or death from any cause, whichever occurs earlier. |
|
E.5.2 | Secondary end point(s) |
The key secondary endpoint is TTNI.
Other secondary efficacy endpoints are TGR, objective response, CR+PR, time to response, time to CR+PR, duration of response, duration of CR+PR, OS, FACT-BR scores, and PFS by investigator.
Safety/PK: • Adverse events, serious adverse events (SAEs), and AEs leading to discontinuation or death, and severity of AEs • Safety laboratory parameters, vital signs, 12-lead electrocardiograms (ECGs), evaluation of left ventricular ejection fraction (LVEF), Karnofsky Performance Scale (KPS)/Lansky Play-Performance Scale (LPPS), and concomitant medications. • Serial or sparse blood sampling at specified time points for determination of plasma concentration-time profiles and PK parameters of vorasidenib and its circulating metabolite AGI-69460. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
TTNI: from randomization to initiation of first subsequent anticancer therapy or death due to any cause TGR as assessed by volume: % increase in tumor volume every 6 mons OS: from date of randomization to death due to any cause OR: best overall response of CR, PR, or MR CR+PR: best overall response of CR or PR Time to response: from date of randomization to first documented CR,PR, or MR Time to CR+PR: from date of randomization to first documented CR or PR for subjects with CR or PR Duration of response: from date of first documented CR, PR, or MR to the earlier of the date of death due to any cause or first documented radiographic PD Duration of CR+PR: from date of first documented CR or PR to the earlier of the date of death due to any cause or first documented radiographic PD |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Israel |
United States |
France |
Netherlands |
Spain |
Switzerland |
Germany |
Italy |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study is defined as the time at which all subjects have discontinued study treatment and completed the OS Follow-up period, died, withdrawn consent from overall study participation, are lost to follow-up, or the Sponsor ends the study, whichever occurs first. Final analysis for OS will be conducted at the end of the study.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 8 |